Overview

Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone when given together with sunitinib malate in treating patients with progressive advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Jaime Merchan
Collaborators:
Bristol-Myers Squibb
Pfizer
Treatments:
Epothilone B
Epothilones
Sunitinib